Company intelligence / Profile preview

Primal Health

Minneapolis, Minnesota, United Statesprimalhealthllc.com ↗

Ownership: Private
Development stage: Other

Overview

Primal Health’s SMMRT™ formula lozenges were evaluated in a National Institutes of Health-funded clinical study, where participants took the product three times daily for six weeks. The results suggest the technology may be highly effective in treating and preventing periodontal disease[3].

Therapeutic areas: Infectious Diseases
Modalities: Small molecule (functional ingredients for microbiome modulation)Microbial therapy (oral microbiome modulatory products)
Industry: Biotech

Drug pipeline

1 asset

PROtektin

Unknown

Partnerships

National Institutes of Health (NIH) – funded clinical studies[3]

Beyond the preview

Go deeper on Primal Health.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Primal Health.